Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- First Online:
- Cite this article as:
- Lammer, J., Malagari, K., Vogl, T. et al. Cardiovasc Intervent Radiol (2010) 33: 41. doi:10.1007/s00270-009-9711-7
- 5.1k Views
Transcatheter arterial chemoembolization (TACE) offers a survival benefit to patients with intermediate hepatocellular carcinoma (HCC). A widely accepted TACE regimen includes administration of doxorubicin-oil emulsion followed by gelatine sponge—conventional TACE. Recently, a drug-eluting bead (DC Bead®) has been developed to enhance tumor drug delivery and reduce systemic availability. This randomized trial compares conventional TACE (cTACE) with TACE with DC Bead for the treatment of cirrhotic patients with HCC. Two hundred twelve patients with Child-Pugh A/B cirrhosis and large and/or multinodular, unresectable, N0, M0 HCCs were randomized to receive TACE with DC Bead loaded with doxorubicin or cTACE with doxorubicin. Randomization was stratified according to Child-Pugh status (A/B), performance status (ECOG 0/1), bilobar disease (yes/no), and prior curative treatment (yes/no). The primary endpoint was tumor response (EASL) at 6 months following independent, blinded review of MRI studies. The drug-eluting bead group showed higher rates of complete response, objective response, and disease control compared with the cTACE group (27% vs. 22%, 52% vs. 44%, and 63% vs. 52%, respectively). The hypothesis of superiority was not met (one-sided P = 0.11). However, patients with Child-Pugh B, ECOG 1, bilobar disease, and recurrent disease showed a significant increase in objective response (P = 0.038) compared to cTACE. DC Bead was associated with improved tolerability, with a significant reduction in serious liver toxicity (P < 0.001) and a significantly lower rate of doxorubicin-related side effects (P = 0.0001). TACE with DC Bead and doxorubicin is safe and effective in the treatment of HCC and offers a benefit to patients with more advanced disease.
KeywordsChemoembolizationHepatocellular carcinomaDoxorubicinDrug-eluting beads
Hepatocellular carcinoma (HCC) is an increasingly common tumor with a poor prognosis and limited systemic treatment options; approximately 80% of patients die within a year of diagnosis. In men, it is the fifth most common cancer worldwide and the third leading cause of cancer-related death [1, 2].
Barcelona Clinic Liver Cancer (BCLC) tumor staging [3, 4] combines the stage of liver disease, tumor stage, clinical performance, and treatment options and is endorsed by the European Association for the Study of Liver Disease (EASL) and the American Association for the Study of Liver Disease (AASLD) . In countries where no systematic screening of cirrhotic patients is performed, 50–75% are diagnosed when HCC is at an advanced stage (BCLC Stage C, Child-Pugh A/B, cancer symptoms present, and/or vascular invasion and extrahepatic spread) . Such patients are precluded from surgery, and for many years doxorubicin had been used for systemic treatment , albeit without a proven survival benefit . Thus, there is interest in new antiangiogenic agents. Recent data have established Sorafenib as the preferred systemic therapy for advanced HCC . For unresectable intermediate-stage HCC (BCLC Stage B, Child-Pugh A/B, with large or multifocal HCC, no vascular invasion or extrahepatic spread), the current standard treatment is transarterial chemoembolization (TACE) .
TACE involves the periodic injection of a chemotherapeutic agent, mixed with embolic material, administered selectively into the feeding arteries of the tumor to potentially obtain higher intratumor drug concentrations compared to intravenous therapy, with occlusion of the blood vessel causing infarction and necrosis . In HCC patients, TACE has achieved partial responses in up to 62% of patients, as well as significantly delayed tumor progression and vascular invasion [10–16]. Llovet et al. were the first to show a statistically significant benefit in survival for chemoembolization using doxorubicin (50–75 mg/m2) and Gelfoam compared with best supportive care (BSC) . Although a survival benefit of TACE over symptomatic treatment or systematic chemotherapy was demonstrated in a meta-analysis of randomized controlled trials, overall survival at 3 years remained low (<30%) for intermediate HCC patients . A further review failed to demonstrate either a survival difference between TACE and embolization alone or superiority of one chemotherapeutic agent over another . Post-TACE complications, e.g., acute liver or renal failure, encephalopathy, ascites, and upper gastrointestinal bleeding, may be severe . There is therefore a requirement for treatment regimens that improve response rates and survival, while reducing the risk of post-TACE complications.
The DC Bead (Biocompatibles UK Ltd.) is a novel drug delivery embolization system, comprising biocompatible, nonresorbable hydrogel beads capable of being loaded with anthracyclin derivatives such as doxorubicin [19, 20], the most widely used chemotherapeutic for the treatment of HCC. Preclinical [21, 22] and clinical [23, 24] studies have shown that TACE with DC Bead results in higher tumor concentrations and lower systemic concentrations of doxorubicin compared to intra-arterial doxorubicin and conventional TACE. Phase I/II studies in HCC have demonstrated promising efficacy with low toxicity [23–26].
This phase II study is the first comparative study designed to evaluate the safety and efficacy of DC Bead with doxorubicin in the treatment of HCC in comparison with conventional TACE (cTACE), the current standard treatment .
Materials and Methods
Patients aged >18 years with HCC unsuitable for resection or percutaneous ablation, (BCLC A/B, without portal invasion or extrahepatic spread) were eligible for the study. Eligibility criteria also included: no previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy), a confirmed diagnosis of HCC according to EASL, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and preserved liver function (Child-Pugh Class A or B). Patients were excluded if they had another primary tumor, advanced liver disease (bilirubin levels >3 mg/dl, AST or ALT >5 × upper limit of normal or >250 U/l), advanced tumoral disease (vascular invasion or extrahepatic spread, or diffuse HCC, defined as >50% liver involvement), or contraindications for doxorubicin administration.
All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guideline on Good Clinical Practice, and relevant local laws and regulations. Ethics committee approval was obtained. Independent Data and Safety Monitoring Committees were established to monitor efficacy and safety data. The study was registered at www.clinicaltrials.gov (NCT00261378), conducted according to the HCC Clinical Trial Design guidelines , and reported according to CONSORT recommendations [28, 29].
This was an international, multicenter, prospective, randomized, single-blind, phase II study. Patients were randomized (1:1) to receive doxorubicin via TACE with DC Bead or conventional TACE (cTACE). Randomization was centralized, with stratification factors of Child-Pugh class (A/B), ECOG performance status (0/1), prior curative (resection or percutaneous ablation) treatment (yes/no), and bilobar disease (yes/no), representing more advanced disease. Randomized treatment allocation was predetermined by an independent statistician and used a randomized permuted block design to ensure that, at the conclusion of the study treatment, group sizes were similar both overall and for each level of stratification factor. The randomization was integrated into the web-based Case Report Form after screening.
Dose selection was based on cTACE treatment protocols of doxorubicin, 50–75 mg/m2. Patients typically receive between 100 and 150 mg in a single treatment session. In two previous dose escalation studies [23, 24], DC Bead loaded with doxorubicin in the range from 25 to 150 mg was shown to be safe and effective even at the highest dose of 150 mg.
In this study, patients in the DC Bead group received 4 ml DC Bead (1 vial of 300–500 μm first, followed by 1 vial of 500–700 μm) loaded with doxorubicin (150 mg per procedure) mixed with nonionic contrast medium. Lipiodol (iodinated poppy seed oil; Guerbet, France) was not used. No dose adjustment was made for bilirubin concentration or body surface area. In the cTACE group, patients received an intra-arterial injection of an emulsion of doxorubicin (50–75 m2 to a maximum of 150 mg, adjusted for bilirubin concentration and body surface area) in lipiodol followed by particle embolization with an embolic agent of the investigator’s choice (Gelfoam particles, Embosphere, Contour SE, Bead Block, PVA particles). In both treatment groups, patients were treated at 2-monhtly intervals [25, 26], received a maximum of three chemoembolizations (at baseline, 2 months, and 4 months), and were followed for 6 months. For patients with bilobar disease who could not be treated superselectively in a single treatment, a second embolization, of the alternative lobe, was performed within 3 weeks of the first procedure (procedure 1B) provided that there was no contraindication due to systemic toxicity and/or clinical performance. Reasons for discontinuation of treatment included ineligibility prior to chemoembolization, progressive disease, and severe systemic toxicity.
In both treatment arms, catheterization was performed via a femoral artery, and superselective embolization of the hepatic artery branches feeding the tumor was performed. The embolization endpoint was defined as stasis in the second- or third-order branches of the right or left hepatic artery. A microcatheter could be used to select a branch feeding the tumor.
Study Hypothesis and Objective
The hypothesis was that treatment of HCC with DC Bead is superior to treatment with cTACE. The objective was to evaluate the safety and 6-month tumor response of chemoembolization with DC Bead vs. cTACE.
Outcomes and Procedures/Assessments
The primary efficacy endpoint was the 6-month tumor response rate, according to the amended EASL response criteria, an accepted method for assessing tumor necrosis following locoregional therapy . According to this amendment, response of target lesions is classified according to the presence and the dimensions of the viable tumor, defined as a tumor that takes up contrast in the arterial phase of radiologic imaging. The primary readers manually traced viable tumor on MRI slices obtained at baseline and after treatment, and computer calculations were made to quantify percentage changes in viable tumor volume and therefore to define the response of target lesions. The emergence of one or more new lesions was considered evidence of progression in the overall patient response assessment, regardless of the response obtained in target lesions. Objective response rate (OR) was defined as complete response plus partial response, and disease control rate as OR plus stable disease.
The primary safety endpoint was the incidence of treatment-related serious adverse events (SAEs) occurring within 30 days of a treatment procedure. Secondary safety outcomes included the incidence and severity of adverse events (AEs) and SAEs, liver function parameters, laboratory abnormalities, and cardiac function (ejection fraction).
The study aimed to reject with 80% power, at a one-sided significance level of α = 0.025, the null hypothesis H0, i.e., πDC Bead = πcTACE against the alternative hypothesis, H1, i.e., πDC Bead > πcTACE, where π denotes the rate of patients in the respective treatment arm with an objective tumor response at 6 months. The study was conducted using an adaptive three-stage group sequential test design within the Δ class of critical values from Wang and Tsiatis . Assuming objective tumor response rates of 55% (DC Bead) and 35% (cTACE), and a total n = 200, the statistical power was approximately 81.3%. Interim analyses were conducted independently and results kept confidential until completion of the trial. Following each interim analysis, the Data Monitoring Committee made recommendations to continue, modify, or stop the trial, based on interim analysis results (stopping criteria at n1 = 60, boundary P-value = 0.00015; n2 = 40, boundary P-value = 0.00258; n3 = 100, boundary P-value = 0.02396).
The primary analysis of efficacy was based on the Modified Intention-to-Treat (MITT) population, defined as all randomized patients who received at least one chemoembolization; this also defined the safety population. The primary safety endpoint was analyzed using the chi-square test and all safety data are presented descriptively.
All other group comparisons were supportive in nature and the secondary efficacy endpoints were analyzed descriptively using appropriate statistical methods for each endpoint. Where statistical modeling was used, baseline stratification factors were included. All endpoints were also presented using descriptive statistical methods and all statistical testing was two-sided at the 5% level of significance. The preplanned analyses of the subgroup of more advanced patients (Child-Pugh B, ECOG 1, bilobar disease, recurrent disease) revealed a clinically relevant trend toward a higher OR rate for DC Bead over cTACE. Supplementary post hoc analyses focused on treatment response and safety were therefore undertaken. The frequency of doxorubicin-related AEs, and of overall AEs, and the level of liver toxicity were explored further. These data were hypothesis-generating in nature, and P-values should be interpreted in the exploratory sense.
Patient characteristics, health status, and tumor burden at baseline
DC Bead (n = 93)
cTACE (n = 108)
Age, years (mean ± SD)
67.3 ± 9.1
67.4 ± 8.8
Etiology of cirrhosisa (HCV/HBV/alcohol/otherb)
Prior curative treatment (no/yes)c
Percutaneous ethanol injectiond
Bilobar disease (no/yes)c
Child-Pugh classification (A/B)c
ECOG performance status (0/1)c
Okuda tumor classification (I/II)
BCLC classification (A/B/C)e
Karnofsky performance status (100/90/80/≤70)
LVEF, % (mean ± SD)
66.2 ± 8.4
64.3 ± 8.2
No. of nodules (1/1+f/2/multinodular)
Mean no. of lesions (range)
Total sum of diameters of HCC lesions, mm (mean ± SD)
88.9 ± 52.1
89.2 ± 59.3)
Mean liver involvement, % (range)
Efficacy (Tumor Response—EASL)
Incidence of serious adverse events within 30 days of a procedure, by stratification (safety population)
DC Bead (n = 93)
cTACE (n = 108)
No. of patients/total
No. of patients/total
No prior curative treatments
Effects of systemic doxorubicin (safety population)
Event/SWOG toxicity grade
DC Bead (n = 93)
cTACE (n = 108)
No. of events
No. of patients
No. of events
No. of patients
Currently, cTACE is the standard first-line treatment for patients with inoperable and intermediate HCC. Although TACE has been in use for several years, the procedure varies widely between centers, with different drugs (doxorubicin, mitomycin, cisplatin, mixtures), embolic agents, doses, and schedules used. Response rates vary and evidence of a survival benefit, particularly at 3 years, is low [15–18]. In the PRECISION V study, cTACE was designed to reflect the current practice of chemoembolization and was standardized to the use of doxorubicin, lipiodol, and an embolic agent.
The DC Bead is a novel drug delivery embolization system that has been designed to deliver a higher and more sustained release of drug directly into the tumor and a low release of drug into the systemic circulation, with the intention to maximize the drug’s effectiveness in terms of response, while significantly reducing its systemic toxicity . Preclinical and clinical studies have demonstrated a higher and prolonged retention of doxorubicin within the tumor after TACE with DC Bead, and lower systemic plasma levels of doxorubicin, compared to cTACE [19–24]. Varela et al. reported significantly lower doxorubicin Cmax and AUC values in DC Bead patients (78.97 ± 38.3 ng/ml and 662.6 ± 417.6 ng/ml min) than in cTACE patients (2341.5 ± 3951.9 ng/ml and 1812.2 ± 1093.7 ng/ml min; P = 0.00002 and P = 0.001, respectively). In another phase I/II clinical study Poon et al. observed low Cmax values (52.8 ± 41.5 ng/ml) even at the highest possible loading of doxorubicin (150 mg), with an average half-life of doxorubicin in plasma of 73.5 ± 22.7 h . Clinical pilot studies in HCC have demonstrated promising efficacy [23–26, 33].
The current study is the first international, multicenter, randomized study designed to evaluate the safety and efficacy of a drug-eluting bead (DC Bead) compared to cTACE for the treatment of HCC. The 6-month OR rate of 52% observed following TACE with DC Bead in this study compares well with previously reported OR rates of 44–82% in phase I/II studies with DC Bead [23–26]. Although in this study statistical superiority in OR rates compared to cTACE could not be demonstrated, a trend toward higher response rates in all categories (complete response, OR, and disease control) was observed for DC Bead over cTACE. Of particular note was the significant reduction in serious liver toxicity and doxorubicin side effects with DC Bead, despite the higher mean total dose administered, enabling the physician to safely deliver higher doses of doxorubicin compared to cTACE.
Post hoc analyses of the predefined stratified groups of higher-risk patients demonstrated that DC Bead provided significant advantages in treating patients with more advanced disease, where improved response and disease control and good tolerability were achieved. This finding is of particular significance for Child-Pugh B and ECOG 1 patients, for whom treatment with chemoembolization has been controversial . Contrary to the observation in the cTACE arm, the response rate for DC Bead in these subgroups was maintained. This suggests that the improved tolerability of DC Bead allows treatment to be repeated according to planned schedule even in these more vulnerable patients. These favorable results establish DC Bead as a viable embolic agent for studies evaluating the combination of TACE with systemic administration of targeted agents such as Sorafenib, in intermediate HCC. In advanced HCC, Sorafenib has shown a survival benefit with low radiological response rates [27–29].
A limitation of the current study is that the number of patients required to show statistically significant superiority was underestimated due to the higher response rate of cTACE (44%) compared with the original assumption (35%) . Robust time-to-progression and survival data would require further randomized controlled trials with longer follow-ups.
In conclusion, TACE with DC Bead and doxorubicin is safe and effective in the treatment of intermediate-stage HCC and offers benefit to patients with more advanced disease.
The study was sponsored by Biocompatibles UK Ltd. The authors acknowledge the contributions of Maria Schoder, Martin Funovics, Christian Loewe, Johanna Moyses, Dimitrios Kelekis, Nikolaos Kelekis, Alexis Kelekis, Emmanouil Emmanouil, Roman Klöckner, Christoph Düber, Gerd Otto, Marcus-Alexander Wörns, Verena Khan, Renate Hammerstingl, Clara Lee, Kathrin Eichler, Olivier Guillaud, Sabine Ficarelli, Nicolas Mennesson, Nathalie Rauscher, Beat Müllhaupt, Dominik Weishaupt, Pietro Majno, Laurent Spahr, Christoph D. Becker, Thierry de Baere, Frederic Deschamps, Pramod Roo, Vlad Ratzui, Phillipe Clluzel, Sebastien Novellas, Albert Tran, Denis Ouzan, Jean Gugenheim, Tim Greten, Timm Kirchhoff, Herbert Rosenthal, Joachim Lotz, Valerie Vilgrain, Annie Sibert, Peter Huppert, Hubertus Wietholtz, A Limmer, Pillippe Otal, Francis Joffre, Julien Auriol, Jean Marie Péron, Peter Waldenberger, Andreas Chemelli, Ivo Graziadei, Juergen Triller, and Ralph Kickuth (n = 52; order based on site recruitment).